Study in conjunction with investigators from Labor Quade and the Johns Hopkins School of Medicine analyzed the longer-term stability of IDM analytes in uncentrifuged peripheral blood samples to allow for increased flexibility in donor sample processing. Study results indicate that broad use of blood processing parameters developed for the measure of metabolites appears to create artificially stringent preanalytical requirements for IDM testing.

MINNEAPOLIS, May 28, 2024 — NMDP BioTherapies (formerly known as the Be The Match BioTherapies), a leader in cell and gene therapy development support, will present a poster at this year’s International Society for Cell & Gene Therapy annual meeting in Vancouver, Canada (ISCT 2024), sharing results of a study of the impacts of delayed whole blood processing on the stability of infectious disease marker analytes during donor qualification for allogeneic cell therapies. Results of the study indicate that leveraging blood processing parameters for stability of metabolites may create artificially stringent preanalytical requirements, such as timelines between sample collection and centrifugation.

“Delayed sample processing when leveraging centralized testing laboratories can be a difficult reality of today’s donor qualification process for allogeneic cell therapies,” said Dr. Joy Aho, Director of Product Management at NMDP BioTherapies. “Our investigation, conducted in conjunction with Labor Quade and the Johns Hopkins School of Medicine, indicates that antibodies are stable and can be reliably tested for up to 120 hours post collection in serological assays and that qualitative results of nucleic acid testing are not materially negatively impacted by changes observed in copy number up to 120 hours post collection.”


Poster Presentation Details

  • Title: Impact of delayed whole blood processing on the stability of infectious disease marker analytes during donor qualification for allogeneic cell therapies
  • Poster number: 857
  • Time: Wednesday, May 29, 7-8:30 p.m.
  • Location: Exhibit and Poster Hall, Vancouver Convention Centre, West Building

NMDP BioTherapies supports organizations that are creating next-generation cell and gene therapies. With access to donors and cord blood units from the NMDP Registry, which is the world’s most diverse registry, and an extensive collection network, NMDP BioTherapies provides a wide variety of cell sourcing options for developers of allogeneic cell and gene therapies so that they can expand treatment options for patients with life-threatening or debilitating diseases.

About NMDP BioTherapies

NMDP BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of NMDP and a research partnership with the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the organization designs solutions that advance the development of cell and gene therapies across the globe.

NMDP BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the NMDP Registry, the world’s most diverse registry of more than 7 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection, and transplant centers worldwide, the organization develops, onboards, trains, and manages expansive collection networks to advance cell therapies. NMDP BioTherapies uses a proven infrastructure consisting of regulatory compliance and managed logistics experts and cell therapy supply chain case managers to successfully transport and deliver regulatory-compliant life-saving therapies across the globe. Through the CIBMTR, NMDP extends services beyond the cell therapy supply chain to include long-term follow-up tracking for FDA-approved CAR-T therapies.

For more information, follow NMDP BioTherapies on LinkedIn or X.

NMDP BioTherapies Media Contact:  

Matt Mayr
(800) 471-4431